Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure

Pharmacotherapy. 2014 Nov;34(11):1121-31. doi: 10.1002/phar.1480. Epub 2014 Aug 28.

Abstract

Study objectives: To compare the frequency of achieving a therapeutic serum digoxin concentration (SDC), defined as 0.5-0.9 ng/ml, by using a simplified nomogram to individualize digoxin dosing with standard dosing practices in patients with heart failure, and to characterize the relationship between genetic polymorphisms of the ABCB1 gene and SDC.

Design: Prospective study with a historical control group.

Setting: Outpatient care center of an urban academic medical center.

Patients: A total of 131 adults with heart failure due to left ventricular dysfunction who were treated with digoxin.

Intervention: Digoxin doses were determined either by the dosing nomogram (65 patients) or standard care (SC; 66 patients) by using historical controls who were randomly selected from a list of SDCs obtained from laboratory records and who had their digoxin doses determined by standard dosing practices.

Measurements and main results: The primary end point was the proportion of patients achieving a steady-state SDC of 0.5-0.9 ng/ml; secondary end points were mean SDC and proportion of patients achieving a steady-state SDC lower than 1.0 ng/ml. Postdistributive steady-state SDCs were measured 2-4 weeks after digoxin dosage adjustment or initiation. Therapeutic SDCs were achieved with similar frequency in both groups (38.7% in the nomogram group vs 34.5% in the SC group, p=0.65); however, more patients in the nomogram group had SDCs lower than 1.0 ng/ml than in the SC group (85.0% vs 44.9%, p<0.001). Mean daily digoxin doses were lower in the nomogram group (149 ± 67 μg vs 177 ± 74 μg, p=0.02), resulting in lower mean SDCs compared with those in the SC group (0.52 ± 0.30 ng/ml vs 1.12 ± 0.58 ng/ml, p<0.001). Patients in the pharmacogenetic substudy provided blood samples for genotyping of three common ABCB1 single nucleotide polymorphisms: C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642). SDCs were not significantly associated with ABCB1 genotypes.

Conclusion: Our simplified digoxin dosing nomogram resulted in lower SDCs compared with standard dosing practices but achieved therapeutic SDCs with similar frequency. A greater proportion of patients dosed according to our nomogram had SDCs lower than 1.0 ng/ml, consistent with consensus guidelines. Genetic polymorphisms of the ABCB1 gene were not associated with SDC.

Trial registration: ClinicalTrials.gov NCT01005602.

Keywords: digoxin; dosing nomogram; heart failure.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / genetics
  • Academic Medical Centers
  • Aged
  • Amino Acid Substitution
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / blood
  • Cardiotonic Agents / pharmacokinetics
  • Cardiotonic Agents / therapeutic use
  • Chicago
  • Digoxin / administration & dosage*
  • Digoxin / blood
  • Digoxin / pharmacokinetics
  • Digoxin / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Heart Failure / etiology
  • Heart Failure / prevention & control*
  • Historically Controlled Study
  • Humans
  • Male
  • Middle Aged
  • Nomograms
  • Outpatient Clinics, Hospital
  • Polymorphism, Single Nucleotide
  • Precision Medicine*
  • Ventricular Dysfunction, Left / blood
  • Ventricular Dysfunction, Left / drug therapy*
  • Ventricular Dysfunction, Left / genetics
  • Ventricular Dysfunction, Left / physiopathology

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • Cardiotonic Agents
  • Digoxin

Associated data

  • ClinicalTrials.gov/NCT01005602